Tryp Therapeutics is a biotechnology firm based in San Diego focused on developing psilocybin-based drugs that treat conditions beyond those of mental health.
The company seeks an expedited regulatory approval process for its products, made possible by psilocybin’s pre-established, favorable safety profile. It aims to improve currently available treatments by decreasing needed dosings, minimizing and improving the tolerability of side effects, and targeting disease sources versus symptoms. Their drugs are intended to be administered as adjuncts to psychotherapy.
Tryp’s initial candidate products are designed to treat pain conditions such as fibromyalgia, complex regional pain syndrome (CRPS), and phantom limb pain, as well as eating disorders — relatively uncommon applications of psychedelic medicine. The company was featured in a Scientific American article titled, “Can Psychedelic Drugs Treat Physical Pain?”. Under its main program, “Psilocybin-for-Neuropsychiatric Disorders” (PFN™), Tryp is pursuing Phase 2A clinical trials at the University of Michigan to assess candidate products in efficacy against fibromyalgia, and Phase 2A clinical trials at the University of Florida to analyze effectiveness for eating disorders.
Tryp has also developed a proprietary formulation called TRP-8803 which has a novel delivery route. TRP-8803 is in a pre-clinical stage as of October 2021 but is intended for use in Phase 2B trials. According to pipeline information on its website, Tryp expects to complete Phase 2B clinical trials for fibromyalgia and phantom limb pain by 2024 and for CRPS by 2025; it expects to begin phase 2B trials for binge eating disorder and hypothalamic obesity –which currently has no FDA-approved therapies– by the end of 2022.
Tryp’s Chief Executive Officer Greg McKee was appointed in April 2021. Its Scientific Advisory Board includes Dr. Robin Carhart-Harris.